Financial Performance - The company's operating revenue for Q3 2021 was ¥88,334,621.36, representing a year-on-year increase of 35.78%[5] - The net profit attributable to shareholders for Q3 2021 was ¥29,675,291.60, reflecting a year-on-year growth of 51.28%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥29,924,298.25, up 61.38% year-on-year[5] - Total revenue for the first three quarters of 2021 reached ¥235,876,946.48, a significant increase of 64% compared to ¥143,911,515.75 in the same period of 2020[22] - Operating profit for the first three quarters of 2021 was ¥86,395,501.55, up from ¥44,771,866.59 in the previous year, indicating a growth of 93%[23] - Net profit for the first three quarters of 2021 was ¥74,756,574.85, compared to ¥38,691,673.97 in 2020, representing an increase of 93%[23] - The total comprehensive income for the third quarter of 2021 was CNY 74,756,574.85, compared to CNY 38,727,693.91 in the same period of 2020, representing an increase of approximately 93%[24] Assets and Equity - The total assets at the end of the reporting period were ¥840,842,239.76, an increase of 183.68% compared to the end of the previous year[6] - The total equity attributable to shareholders at the end of the reporting period was ¥758,692,152.47, up 267.61% year-on-year[6] - Total assets as of September 30, 2021, amounted to ¥840,842,239.76, a substantial rise from ¥296,410,327.69 at the end of 2020[21] - The company's equity attributable to shareholders increased to ¥758,692,152.47 from ¥206,387,319.77, a growth of 267%[21] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥44,331,460.00, reflecting a year-on-year increase of 54.17%[6] - Cash flow from operating activities for the first nine months of 2021 was CNY 44,331,460.00, compared to CNY 28,755,128.93 in the same period of 2020, indicating a year-over-year increase of 54%[28] - Cash inflow from investment activities for the first nine months of 2021 was CNY 64,252,050.00, significantly higher than CNY 22,310,762.41 in the same period of 2020, marking an increase of 188%[28] - The net cash flow from financing activities for the first nine months of 2021 was CNY 456,587,826.08, compared to a net outflow of CNY 64,676,514.85 in the same period of 2020, showing a turnaround of CNY 521,264,340.93[29] Research and Development - Research and development expenses for Q3 2021 totaled ¥7,991,320.76, accounting for 9.05% of operating revenue, an increase of 0.08 percentage points year-on-year[6] - Research and development investment reached 7.99 million RMB in Q3 2021, a year-on-year increase of 36.95%[16] - Research and development expenses for the first three quarters of 2021 were ¥20,831,586.19, compared to ¥17,279,484.98 in the same period of 2020, an increase of 20%[22] Market Expansion and Operations - The company is actively expanding its domestic and international markets, with a focus on increasing marketing efforts and brand recognition[16] - The company has established new communication mechanisms with overseas agents to mitigate the impact of the COVID-19 pandemic on international marketing efforts[16] - The company experienced significant growth in performance due to the impact of the COVID-19 pandemic in the previous year[9] - The domestic market demand for the company's main products has recovered and grown, particularly in the sales of chemiluminescent products[14] Production and Capacity - The new factory in Hunan has expanded the company's production capacity and optimized product structure, enhancing competitiveness[14] - The company obtained 33 medical device registration certificates during the reporting period, including 26 new certificates for the automated allergy testing platform, Subok[14] Financial Stability - Total liabilities decreased to ¥82,150,087.29 from ¥90,023,007.92, showing a reduction of approximately 9%[20] - The company's cash and cash equivalents reached ¥146,239,656.14, up from ¥58,815,105.12, indicating a growth of 148%[18] - The total cash and cash equivalents at the end of the third quarter of 2021 amounted to CNY 146,239,656.14, up from CNY 42,781,352.91 at the end of the same quarter in 2020[29]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1]. - The company reported a significant increase in revenue, with a year-on-year growth of 25% in the first half of 2021[13]. - The company expects to achieve a revenue target of 1 billion yuan for the full year 2021, representing a 20% increase from 2020[15]. - The company's operating revenue for the first half of the year reached ¥147,542,325.12, representing an increase of 87.11% compared to the same period last year[22]. - Net profit attributable to shareholders increased by 136.32% to ¥45,081,283.25, while the net profit after deducting non-recurring gains and losses surged by 590.96% to ¥45,160,515.65[22]. - The company achieved total revenue of 147.54 million yuan, an increase of 87.11% year-on-year[64]. - The net profit attributable to the parent company was 45.08 million yuan, up 136.32% year-on-year[64]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the first half of 2021, representing a 20% year-over-year growth[138]. User Growth and Market Expansion - User data indicates a growth in active users by 15% compared to the previous year, reaching 1.5 million active users[1]. - User data showed that the number of tests conducted increased by 30% compared to the same period last year, indicating a growing demand for the company's diagnostic products[14]. - User data showed a 15% increase in active users, reaching 2 million by the end of the reporting period[110]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1]. - The company is expanding its market presence in Europe, aiming for a 15% market share by the end of 2022[13]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share within the next two years[110]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[138]. Product Development and Innovation - New product development includes the launch of two innovative diagnostic kits, projected to contribute an additional RMB 30 million in revenue[1]. - New product launches include the "Nabok" series, which utilizes advanced nanomagnetic chemiluminescence technology for autoimmune disease detection, enhancing sensitivity and speed[14]. - The company plans to invest RMB 50 million in technology upgrades to improve operational efficiency[1]. - The company plans to invest 100 million yuan in technology upgrades and facility expansions over the next two years to support growth[15]. - The company is focusing on the development of rapid detection methods that are sensitive and suitable for automation, which will enhance its product offerings in the international market[51]. - The company is developing a fully automated nano magnetic particle chemiluminescence allergy project covering 25 items, with a projected revenue of RMB 2,600.00 million and a development cost of RMB 156.38 million[53]. - The company is working on a new model of the SMART 6500 chemiluminescence analyzer, with a development cost of RMB 104.16 million and an expected revenue of RMB 49.81 million[53]. Research and Development - Research and development efforts are focused on improving the accuracy of allergy testing products, with a projected completion date for new tests by Q4 2021[14]. - The total R&D investment for the period was approximately ¥12.84 million, representing a 12.20% increase compared to the previous period[48]. - The company has filed a total of 110 patent applications, including 88 invention applications, and has been granted 41 patents, of which 19 are invention patents[46]. - The company has increased its R&D personnel to 70, representing 18.87% of the total workforce, with total R&D compensation amounting to RMB 713.37 million[60]. - The company is focusing on continuous R&D investment in the allergy and autoimmune fields to maintain its competitive edge[65]. Strategic Partnerships and Acquisitions - A strategic acquisition of a local biotech firm is in progress, expected to enhance the company's R&D capabilities and product offerings[1]. - Strategic partnerships are being formed with key healthcare providers to enhance distribution channels and increase product accessibility[14]. - The company is exploring potential acquisitions to diversify its product offerings and strengthen its market position[15]. - The company is exploring strategic acquisitions to enhance its product offerings, with a budget of $100 million allocated for potential deals[110]. - There are ongoing discussions regarding potential mergers and acquisitions to enhance product offerings and market reach, with a budget of 500 million RMB allocated for this purpose[138]. Financial Health and Investments - The company plans to address the funding gap through self-raised funds[150]. - The total assets of the company increased by 12% to $1.2 billion, reflecting strong financial health[122]. - The company has maintained a strong financial position with no non-operating fund occupation reported from major shareholders[140]. - The company reported a cash inflow from operating activities of CNY 160,884,010.47, compared to CNY 86,345,325.49 in the first half of 2020, indicating an increase of 86.1%[186]. - The company received CNY 518,890,428.40 from investment absorption, indicating strong investor confidence[189]. Risks and Challenges - The company has identified potential risks related to regulatory changes, which could impact future operations[1]. - The company faces risks related to the limited market space for food-specific IgG testing products due to academic controversies[70]. - There is a risk of revenue decline for food-specific IgG testing products as hospitals and third-party testing institutions reduce or stop procurement[70]. - The reliance on imported core raw materials poses a risk to the company's production and operational stability[72]. - The COVID-19 pandemic has led to significant fluctuations in performance, particularly affecting the willingness of patients to seek non-urgent testing[73]. Corporate Governance and Compliance - The company has implemented a strict quality management system in compliance with ISO13485 standards[66]. - The company is classified as a key pollutant discharge unit by environmental protection authorities, indicating a focus on compliance with environmental regulations[92]. - The company has established an emergency response plan for environmental incidents, including training and communication protocols[97]. - The company confirmed that its actual controlling shareholders and related parties have fulfilled their commitments regarding shareholding and management, ensuring no third-party disputes or restrictions on shares[103]. - The company is committed to minimizing related party transactions and ensuring fair market practices[125].

Financial Performance - Operating revenue reached CNY 60,990,393.72, a 199.47% increase year-on-year[8] - Net profit attributable to shareholders was CNY 13,336,533.53, compared to a loss of CNY 5,333,030.55 in the same period last year[8] - Basic earnings per share improved to CNY 0.23 from a loss of CNY -0.11 in the same period last year[8] - Operating profit for Q1 2021 was ¥14,534,958.39, compared to a loss of ¥6,588,367.89 in Q1 2020, indicating a turnaround in profitability[30] - Net profit for Q1 2021 was ¥13,336,533.53, recovering from a net loss of ¥5,333,030.55 in Q1 2020[31] - The company achieved an investment income of ¥2,567,085.16 in Q1 2021, contributing positively to overall profitability[30] - In Q1 2021, the company reported a total comprehensive income of CNY 13,744,318.41, compared to a loss of CNY 556,761.11 in Q1 2020[34] Asset Growth - Total assets increased by 164.21% to CNY 783,139,544.11 compared to the end of the previous year[8] - As of March 31, 2021, total assets reached ¥783,139,544.11, a significant increase from ¥296,410,327.69 on December 31, 2020, reflecting a growth of approximately 164%[22] - Total current assets amounted to ¥608,679,217.30, compared to ¥158,654,487.72 at the end of 2020, indicating a growth of about 284%[22] - The company's total liabilities decreased to ¥66,949,934.56 from ¥90,023,007.92, representing a reduction of approximately 26%[23] - The total equity attributable to shareholders increased to ¥716,189,609.55 from ¥206,387,319.77, marking a growth of around 248%[24] - The total assets of the company amounted to ¥752,820,621.65 in Q1 2021, compared to ¥260,183,218.03 in Q4 2020, indicating substantial growth in asset base[28] Cash Flow and Financing - The net cash flow from operating activities was CNY 7,445,872.43, a significant recovery from a negative cash flow of CNY -10,450,769.74 in the previous year[8] - The company reported a cash inflow from financing activities of ¥479.47 million, a dramatic increase of 24,645.27% due to IPO fundraising[16] - The company raised CNY 518,890,428.41 from financing activities in Q1 2021, a substantial increase from CNY 20,000,000.00 in Q1 2020[37] - The net cash flow from financing activities was CNY 479,469,346.49 in Q1 2021, compared to CNY 1,937,620.40 in Q1 2020, showing a notable increase[37] - The ending cash and cash equivalents balance for Q1 2021 was CNY 506,416,822.95, a significant increase from CNY 77,883,684.47 in Q1 2020[37] Shareholder Information - The total number of shareholders reached 2,828 by the end of the reporting period[12] - The largest shareholder, Hai Rui Xiang Tian Biological Technology (Group) Co., Ltd., holds 55.66% of the shares[12] Research and Development - R&D expenditure as a percentage of operating revenue decreased to 10.67% from 26.78%[8] - Research and development expenses rose to ¥6.51 million, an increase of 19.35% from ¥5.45 million in the previous year, indicating ongoing investment in innovation[16] - Research and development expenses for Q1 2021 were ¥6,508,135.29, up from ¥5,453,130.12 in Q1 2020, highlighting continued investment in innovation[30] Liabilities and Debt Management - Long-term borrowings decreased by 84.53% to ¥3.71 million from ¥23.98 million, attributed to the replacement of loans with IPO funds[15] - The company’s total liabilities decreased to ¥36,859,018.34 in Q1 2021 from ¥54,431,689.38 in Q4 2020, reflecting improved financial health[28] - Total liabilities rose from CNY 90,023,007.92 to CNY 98,235,445.21, with current liabilities totaling CNY 63,227,410.59[43] - The company has a long-term loan of CNY 23,982,978.81, indicating a stable debt structure[43] Inventory and Receivables - Accounts receivable stood at ¥25,391,222.85, down from ¥29,898,529.29, showing a decrease of about 15%[22] - Inventory levels were reported at ¥60,631,082.80, slightly down from ¥61,947,687.01, indicating a decrease of approximately 2%[22] - Other receivables increased by 578.63% to ¥8.42 million, primarily due to interest accrual on idle fundraising deposits[15] Market and Product Development - The company did not report any new products or technologies in this quarter[49] - There were no updates on market expansion or mergers and acquisitions during the call[49]

Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 3 per 10 shares, totaling approximately RMB 18.9175 million, which accounts for 33.41% of the net profit attributable to shareholders for 2020[5]. - The company has not proposed any other forms of profit distribution aside from cash dividends[5]. - The company’s profit distribution plan has been approved by the board and requires shareholder meeting approval[5]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 25% compared to the previous year[12]. - In 2020, the company's operating revenue was CNY 221.86 million, a decrease of 14.38% compared to CNY 259.13 million in 2019[22]. - The net profit attributable to shareholders was CNY 56.62 million, down 11.31% from CNY 63.84 million in 2019[22]. - The net profit after deducting non-recurring gains and losses decreased by 29.99% to CNY 42.75 million[22]. - The company's total assets increased by 4.67% to CNY 296.41 million at the end of 2020[22]. - The net assets attributable to shareholders increased by 37.93% to CNY 206.39 million[22]. - The basic earnings per share were CNY 1.20, down 11.11% from CNY 1.35 in 2019[23]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[5]. - The company has not violated decision-making procedures for external guarantees[7]. - There are no special arrangements for corporate governance noted in the report[8]. - The company has disclosed all related party transactions in accordance with legal and regulatory requirements, ensuring transparency[160]. - There are no undisclosed related party transactions that should have been reported under applicable laws and regulations[160]. Research and Development - Research and development efforts are focused on improving existing diagnostic technologies, with a budget allocation of 10% of total revenue for R&D activities[12]. - The total R&D investment for the year was CNY 24.13 million, a decrease of 5.14% from the previous year, while the R&D investment as a percentage of revenue increased to 10.88% from 9.82%[67]. - The company has obtained 131 product registration certificates, with 52 products receiving EU CE certification, and holds a total of 41 patents, including 19 invention patents[65]. - The company is currently developing a fully automated nanomagnetic chemiluminescence self-immune detection product, with a total expected investment of CNY 16.23 million[70]. Market Expansion and Strategy - The company is expanding its market presence by entering new regions, with plans to establish partnerships in Southeast Asia by the end of 2021[12]. - The company expects continued growth in the next fiscal year, projecting a revenue increase of 20% to 1.44 billion RMB[14]. - The company aims to enhance its product offerings in the autoimmune disease detection market, maintaining a competitive advantage with a rich menu of chemiluminescence products[71]. - The company plans to enhance its market share in the allergy testing field by expanding its product offerings and improving service quality[131]. Risks and Challenges - The company has outlined potential risks in the report, which investors should be aware of[6]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company faces risks related to the development and registration of new products, which typically require over one year for completion[88]. - The company is at risk of its enzyme-linked immunosorbent assay products being replaced by chemiluminescence products, which are becoming the mainstream diagnostic method[89]. Operational Efficiency - The implementation of the "two-invoice system" is expected to streamline operations and reduce costs, potentially increasing profit margins by 5%[13]. - The company employs a procurement model that emphasizes the stability of raw material quality, establishing long-term relationships with qualified suppliers[37]. - The production model is based on "sales-driven production," ensuring safety stock levels while responding to customer orders[39]. Corporate Governance - The actual controllers hold 67.92% of the voting rights, raising concerns about potential improper control[97]. - The actual controllers confirmed that their shares are legally held without any pledges or disputes[144]. - The company has committed to ensuring that the contents of the prospectus do not contain false records, misleading statements, or significant omissions, and will bear legal responsibility for the accuracy and completeness of the information provided[171]. Shareholder Commitments - The actual controller and shareholders committed to not transferring or entrusting the management of their shares for 36 months post-IPO[141]. - If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period will automatically extend by 6 months[142]. - The company will strictly adhere to regulations regarding share reduction after the lock-up period, ensuring stable operations[144]. Product Development and Innovation - New product launches include the "Nabok" brand, which utilizes advanced nanomagnetic chemiluminescence technology for autoimmune disease detection, enhancing sensitivity and speed[13]. - The company has developed core technologies in enzyme-linked immunoassay and chemiluminescence, achieving significant advancements in sensitivity and specificity[62]. - The company aims to replace high-priced imported enzyme-linked immunosorbent assay products with its own chemiluminescence products in the autoimmune detection field[36].